Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International)

Merck & Co. Inc. demonstrated its liking for Addex Pharmaceuticals AG's approach to modulating glutamate receptors by entering a second deal with the Swiss firm in consecutive months. (BioWorld International)

Paion AG got its stroke drug desmoteplase back on track by signing a new agreement with its existing partner H. Lundbeck A/S, under which the latter firm will take on future development and global commercialization responsibility for the compound. (BioWorld International)

Paion AG got its stroke drug desmoteplase back on track by signing a new agreement with its existing partner H. Lundbeck A/S, under which the latter firm will take on future development and global commercialization responsibility for the compound. (BioWorld International)